How severe is CVE-2024-2275?

CVE-2024-2275 has a CVSS 3.x base score of 2.4, rated low severity. It is exploitable over network with low attack complexity, requires high privileges and user interaction. Impact on confidentiality is none, integrity low, and availability none.

Is CVE-2024-2275 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (36th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2024-2275?

CVE-2024-2275 affects Bdtask G-prescription Gynaecology & Obs Consultation. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2024-2275?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.

Does CVE-2024-2275 have an EU (EUVD) identifier?

Yes. CVE-2024-2275 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2024-27230.

When was CVE-2024-2275 published?

CVE-2024-2275 was published on 2024-03-08 and last updated on 2026-06-17.

CVE-2024-2275

CVE-2024-2275 is a low-severity vulnerability in Bdtask G-prescription Gynaecology & Obs Consultation with a CVSS 3.x base score of 2.4. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-79.

Key facts

Severity: Low (CVSS 3.x base score 2.4)
CVSS v2: 3.3
EPSS exploit prediction: 0% (36th percentile)
Actively exploited: Not listed in CISA KEV
EU (EUVD) id: EUVD-2024-27230
Weakness: CWE-79
Affected product: Bdtask G-prescription Gynaecology & Obs Consultation
Published: 2024-03-08
Last modified: 2026-06-17

Description

A vulnerability, which was classified as problematic, was found in Bdtask G-Prescription Gynaecology & OBS Consultation Software 1.0. Affected is an unknown function of the component OBS Patient/Gynee Prescription. The manipulation of the argument Patient Title/Full Name/Address/Cheif Complain/LMP/Menstrual Edd/OBS P/OBS Alc/Medicine Name/Medicine Type/Ml/Dose/Days/Comments/Template Name leads to cross site scripting. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be used. The identifier of this vulnerability is VDB-256044. NOTE: The vendor was contacted early about this disclosure but did not respond in any way.

Frequently asked questions

What is CVE-2024-2275?: A vulnerability, which was classified as problematic, was found in Bdtask G-Prescription Gynaecology & OBS Consultation Software 1.0. Affected is an unknown function of the component OBS Patient/Gynee Prescription. The manipulation of the argument Patient Title/Full Name/Address/Cheif Complain/LMP/Menstrual Edd/OBS P/OBS Alc/Medicine Name/Medicine Type/Ml/Dose/Days/Comments/Template Name leads to cross site scripting. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be used. The identifier of this vulnerability is VDB-256044. NOTE: The vendor was contacted early about this disclosure but did not respond in any way.
How severe is CVE-2024-2275?: CVE-2024-2275 has a CVSS 3.x base score of 2.4, rated low severity. It is exploitable over network with low attack complexity, requires high privileges and user interaction. Impact on confidentiality is none, integrity low, and availability none.
Is CVE-2024-2275 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (36th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2024-2275?: CVE-2024-2275 affects Bdtask G-prescription Gynaecology & Obs Consultation. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2024-2275?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
Does CVE-2024-2275 have an EU (EUVD) identifier?: Yes. CVE-2024-2275 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2024-27230.
When was CVE-2024-2275 published?: CVE-2024-2275 was published on 2024-03-08 and last updated on 2026-06-17.

References

Affected products (1)

cpe:2.3:a:bdtask:g-prescription_gynaecology_\&_obs_consultation:1.0:*:*:*:*:*:*:*

More vulnerabilities in Bdtask G-prescription Gynaecology & Obs Consultation

CVE-2024-2277 — Medium (CVSS 4.3): A vulnerability was found in Bdtask G-Prescription Gynaecology & OBS Consultation Software 1.0 and classified as…
CVE-2024-2276 — Low (CVSS 2.4): A vulnerability has been found in Bdtask G-Prescription Gynaecology & OBS Consultation Software 1.0 and classified as…
CVE-2024-2274 — Low (CVSS 2.4): A vulnerability, which was classified as problematic, has been found in Bdtask G-Prescription Gynaecology & OBS…

All CVEs affecting Bdtask G-prescription Gynaecology & Obs Consultation →

Other CWE-79 (Cross-site Scripting (XSS)) vulnerabilities

CVE-2025-49410 — Critical (CVSS 10.0): Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Imran Emu TC…
CVE-2024-47875 — Critical (CVSS 10.0): DOMPurify is a DOM-only, super-fast, uber-tolerant XSS sanitizer for HTML, MathML and SVG. DOMpurify was vulnerable to…
CVE-2024-6886 — Critical (CVSS 10.0): Improper Neutralization of Input During Web Page Generation (XSS or 'Cross-site Scripting') vulnerability in Gitea…
CVE-2023-45144 — Critical (CVSS 10.0): com.xwiki.identity-oauth:identity-oauth-ui is a package to aid in building identity and service providers based on…
CVE-2023-45138 — Critical (CVSS 10.0): Change Request is an pplication allowing users to request changes on a wiki without publishing the changes directly.…
CVE-2022-4361 — Critical (CVSS 10.0): Keycloak, an open-source identity and access management solution, has a cross-site scripting (XSS) vulnerability in the…

Browse all CWE-79 (Cross-site Scripting (XSS)) vulnerabilities →